Voya Investment Management LLC Acquires 3,653 Shares of Karyopharm Therapeutics Inc (KPTI)

Voya Investment Management LLC grew its holdings in Karyopharm Therapeutics Inc (NASDAQ:KPTI) by 24.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,661 shares of the company’s stock after purchasing an additional 3,653 shares during the period. Voya Investment Management LLC’s holdings in Karyopharm Therapeutics were worth $317,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. UBS Group AG raised its holdings in shares of Karyopharm Therapeutics by 761.8% in the first quarter. UBS Group AG now owns 19,632 shares of the company’s stock valued at $264,000 after purchasing an additional 17,354 shares during the last quarter. Citigroup Inc. raised its holdings in shares of Karyopharm Therapeutics by 502.4% in the first quarter. Citigroup Inc. now owns 21,330 shares of the company’s stock valued at $286,000 after purchasing an additional 17,789 shares during the last quarter. Cubist Systematic Strategies LLC raised its holdings in shares of Karyopharm Therapeutics by 2,536.0% in the first quarter. Cubist Systematic Strategies LLC now owns 25,385 shares of the company’s stock valued at $341,000 after purchasing an additional 24,422 shares during the last quarter. Strs Ohio acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $440,000. Finally, Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $564,000. Institutional investors own 71.57% of the company’s stock.

A number of research firms have recently issued reports on KPTI. Canaccord Genuity reiterated a “buy” rating and issued a $27.00 price objective on shares of Karyopharm Therapeutics in a report on Tuesday, August 7th. BidaskClub downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, September 29th. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 3rd. Robert W. Baird reiterated a “buy” rating and issued a $25.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, August 8th. Finally, ValuEngine downgraded shares of Karyopharm Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 11th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Karyopharm Therapeutics has a consensus rating of “Buy” and an average target price of $22.90.

In related news, insider Sharon Shacham sold 12,500 shares of the business’s stock in a transaction on Monday, October 8th. The shares were sold at an average price of $15.75, for a total transaction of $196,875.00. Following the transaction, the insider now directly owns 715,274 shares in the company, valued at $11,265,565.50. The sale was disclosed in a filing with the SEC, which is available through this link. Also, major shareholder Ltd Chione sold 20,000 shares of the business’s stock in a transaction on Monday, July 23rd. The stock was sold at an average price of $18.66, for a total transaction of $373,200.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 867,305 shares of company stock worth $17,302,128. 13.26% of the stock is owned by corporate insiders.

Shares of KPTI opened at $12.52 on Friday. Karyopharm Therapeutics Inc has a 1-year low of $9.00 and a 1-year high of $21.71.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Tuesday, August 7th. The company reported ($0.60) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.21. The firm had revenue of $19.89 million for the quarter, compared to analyst estimates of $5.97 million. Equities analysts expect that Karyopharm Therapeutics Inc will post -3.18 earnings per share for the current year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.

Recommended Story: How accurate is the Rule of 72?

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply